Merck (MRK) Interest & Investment Income (2011 - 2013)
Merck (MRK) reported Interest & Investment Income of $57.0 million for Q1 2013, up 3.64% year-over-year from $55.0 million in Q1 2012, and up 3.64% quarter-over-quarter from $55.0 million in Q4 2012.
Merck (MRK) Interest & Investment Income (2011 - 2013) Analysis & Trends
Merck (MRK) has 3 years of Interest & Investment Income data on file, last reported at $57.0 million in Q1 2013.
- Interest & Investment Income for Q1 2013 came in at $57.0 million, up 3.64% year-over-year; the trailing twelve-month figure through Mar 2013 was $214.0 million (changed N/A YoY), and the FY2012 annual result was $1.8 billion, changed 0.0% from the prior year.
- Interest & Investment Income improved to $57.0 million in Q1 2013 per MRK's latest filing, from $55.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $57.0 million in Q1 2013 and troughed at $32.0 million in Q3 2011.
- A 3-year average of $48.2 million and a median of $51.0 million in 2012 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2012 and 2013: Interest & Investment Income jumped 46.88% in 2012, then gained 3.64% in 2013.
- A 3-year view of Interest & Investment Income shows it stood at $43.0 million in 2011, then gained by 27.91% to $55.0 million in 2012, then grew by 3.64% to $57.0 million in 2013.
- Business Quant data shows MRK's Interest & Investment Income at $57.0 million in Q1 2013, $55.0 million in Q4 2012, and $47.0 million in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 57.00 Mn |
| Dec 31, 2012 | 55.00 Mn |
| Sep 30, 2012 | 47.00 Mn |
| Mar 31, 2012 | 55.00 Mn |
| Dec 31, 2011 | 43.00 Mn |
| Sep 30, 2011 | 32.00 Mn |